A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
Clinical Trial
[키워드] accelerated
acute respiratory distress
acute respiratory distress syndrome
addition
alpha-1 antitrypsin
Anti-inflammatory
ARDS
biochemically
changes in
circulating
Clinical outcome
clinical trial
Concentration
coronavirus
COVID-19
Cytokines
develop
double-blind
EudraCT
feasible
febrile
Grifols
groups
IL-10
IL-1β
IL-6
IL-8
Inflammation
interleukin-6
intravenous
moderate
Mortality
multicenter
Necrosis
patients
patients receiving placebo
patients with COVID-19
phase 3 trial
Placebo
placebo-controlled trial
plasma
primary endpoint
pro-inflammatory
progression
Randomized
randomized control trial
randomized control trial.
receive
receptor
reduce
Safe
Secondary endpoints
severe ARDS
severe coronavirus disease
Support
syndrome
the placebo group
therapeutic
Tolerability
Treatment
treatment group
Trial
ventilator
ventilator-free day
was increased
were assessed
[DOI] 10.1016/j.medj.2022.03.001 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/j.medj.2022.03.001 PMC 바로가기 [Article Type] Clinical Trial